Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Athens protocol for corneal ectasia: experience of first cases

Poster Details

First Author: F.Faria-Correia PORTUGAL

Co Author(s):    T. Monteiro   L. Oliveira   F. Vaz   R. Ambrosio Jr.           

Abstract Details

Purpose:

Combination of excimer laser and crosslinking allows regularization of the anterior corneal surface and a stabilization of the ectatic process. The Athens Protocol is an approach that combines PTK, PRK-topoguided and crosslinking for treatment of corneal ectasia. The purpose of this study is to present the results of our initial cases treated with this therapheutic modality.

Setting:

Instituto CUF Porto/Hospital CUF Porto

Methods:

Twelve eyes of corneal ectasia were submitted to Athens protocol (combined treatment of PTK, PRK-topoguided and crosslinking). Clinical data and corneal tomogragh findings (Pentacam HR, Oculus, Wetzlar, Germany) prior to surgery and throughout the postoperative period were registered and analyzed.

Results:

During the postoperative follow-up, we recorded an improvement in best-corrected visual acuity (0.52 vs 0.78, p = 0.017). No loss of lines of vision were reported. In the anterior curvature maps, regularization of the anterior surface was verified, with reduction of the maximum point of curvature (53.08 vs 49.56, p = 0.005). Postoperative corneal densitometry reveals an anterior hyperreflective peak in all cases. Corneal haze was a common postoperative finding in all procedures submitted to the procedure. No other postoperative complications were reported.

Conclusions:

In our initial experience, the Athens Protocol proved to be an effective and safe procedure. It allowed the regularization of the anterior surface of the cornea, improving visual acuity of the patients. There was no progression of the disease during the follow-up period. The incidence of postoperative complications is low, being haze the most frequent one.

Financial Disclosure:

receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented.

Back to Poster listing